Pharmacologic management of keratomycoses.
Fungal corneal infections can be very difficult to treat. An evolving understanding of the pharmacology of the currently available antifungal agents has led to improved medical treatment of the keratomycoses. The pharmacology, pharmacokinetics, spectrum of activity and toxicity of these agents is reviewed and promising new antifungal compounds and modes of treatment are discussed.
Johns
K J
KJ
Department of Ophthalmology, Vanderbilt University School of Medicine, Nashville, Tennessee.
O'Day
D M
DM
D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D003316:Corneal Diseases / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D015394:Molecular Structure; D009181:Mycoses / Q000188:drug therapy*; D011090:Polyenes / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000935:Antifungal Agents; D007093:Imidazoles; D011090:Polyenes; D011743:Pyrimidines